Pfizer, Haleon

Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Cuts Stake in Haleon PLC with $2.6 Billion Share Sale
Pfizer has reduced its stake in the British healthcare company Haleon PLC to 7.3% by selling £2.5 billion ($3 billion) worth of shares, according to a bookrunner for the sale. J.P. Morgan Securities PLC reported Wednesday that Pfizer Inc.
Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Pfizer Sells GBP 2.50 Bln Of Shares In Haleon
Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare
Pfizer pares back Haleon stake in £2.5bn sale
Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares in a £2.5bn sale.
UPDATE: Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale
The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% holding in Haleon in May last year.
Pfizer to sell 700M ordinary shares of Haleon
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of
What To Expect From PFE Stock In 2025?
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.
Haleon (NYSE:HLN) Cut to Equal Weight at Morgan Stanley
Morgan Stanley downgraded shares of Haleon (NYSE:HLN – Free Report) from an overweight rating to an equal weight rating in a ...
devdiscourse12h
Jury Hits Bayer with $100 Million Verdict Over PCB Controversy
A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...
Haleon Pioneers New Era in Pain Management Education at DUPHAT 2025
Haleon unveils new initiative at DUPHAT 2025, offering sophisticated pain management solutions with research and training for ...
Haleon plc (NYSE:HLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Haleon plc (NYSE:HLN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research ...
devdiscourse20h
EU's Bid to Reform Medical Device Market amidst Trade Tensions
Health news updates include the EU contemplating curbs on Chinese medical device makers, Pfizer reducing its stake in Haleon, toothpaste lawsuits over fluoride, Eli Lilly’s stock drop, biopharma ...
KamCity2d
Sensodyne Launches New Clinical Repair Range
Haleon’s Sensodyne brand is launching a new Clinical Repair toothpaste range this month, comprising two variants – Deep Clean and Active White.
bovnews4d
HLN’s Recent Drop: What’s Causing the Decline?
On Friday, Haleon PLC – ADR (HLN) stock saw a decline, ending the day at $9.1 which represents a decrease of $-0.39 or -4.11% from the prior close of $9.49. The stock opened at $9.23 and touched a low ...